Skip to main content
. 2021 Apr 16;53(4):667–680. doi: 10.1038/s12276-021-00596-w

Fig. 7. Model of hypothesized OPTN regulation of NRF2, ROS, and osteoclastogenesis.

Fig. 7

RANKL treatment generates ROS secondary messengers that activate NFATc1 and other genes involved in osteoclastogenesis. ROS homeostasis, including ROS signaling, is maintained by antioxidants, which are in turn transcriptionally regulated by NRF2 and modulated by OPTN.